Publications by authors named "S Scartoni"
Article Synopsis
- Elacestrant, a treatment for estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer, showed significantly longer progression-free survival (PFS) compared to standard endocrine therapy (SOC) for patients with ESR1 mutations who had previously received ET plus CDK4/6 inhibitors.
- In a phase III trial named EMERALD, patients were randomly assigned to receive either elacestrant or SOC, and the results indicated that those with ESR1 mutations and prior ET plus CDK4/6i usage of 12 months or more had a notably longer median PFS with elacestrant (8.6 months) versus SOC (1.9 months).
- The observed benefits of elacestrant
Article Synopsis
- Elacestrant is a newly approved oral treatment that has shown effectiveness in women with metastatic hormone receptor-positive (HR+) breast cancer, especially those who did not respond to previous therapies.
- A recent study analyzed patients who previously received fulvestrant and found that those treated with elacestrant had better survival rates without disease progression compared to standard endocrine therapy, regardless of mutations in certain genes.
- Elacestrant was also tested in patient-derived models, showing it is effective in cancers resistant to other treatments like fulvestrant, offering a new therapeutic option for patients with HR+/HER2- breast cancer who have relapsed.
Multimodal analgesia constitutes a common strategy in pain management. A tramadol hydrochloride 75 mg/dexketoprofen 25 mg oral fixed combination (TRAM/DKP 75 mg/25 mg) has been recently registered and released in Europe for the treatment of moderate-to-severe acute pain. This paper provides additional analyses on the results of two phase III clinical trials (DEX-TRA-04 and DEX-TRA-05) on postoperative pain to document its sustained effect.
View Article and Find Full Text PDFBackground: Tachykinins have been implicated in the pathophysiology of IBS with diarrhoea (IBS-D). Our aim was to study the efficacy and safety of ibodutant, a selective neurokinin-2 (NK2) receptor antagonist, in patients with IBS-D.
Methods: This multinational double-blind, placebo-controlled study recruited 559 patients with IBS-D according to Rome III criteria.
Background: Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk. We sought to determine whether febuxostat fixed dose achieves a better sUA control than allopurinol while preserving renal function in TLS prevention.
Patients And Methods: Patients with hematologic malignancies at intermediate to high TLS risk grade were randomized to receive febuxostat or allopurinol, starting 2 days before induction chemotherapy, for 7-9 days.